Catalyst Pharmaceuticals Partners Inc. (NASDAQ: CPRX) shares galloped 9% to $3.26. The company said Monday a late-stage study showed its Firdapse treatment benefitted sufferers of Lambert-Eaton myasthenic syndrome, an autoimmune disorder that causes muscle weakness. Share volume was 1.4 million, towering over an all-day average of 208,000
